A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Inclusion Criteria:

   - Signed written informed consent

   - Diagnosis of RCC with clear-cell or predominant clear-cell histology

   - Subjects with non-metastatic disease (M0) fulfilling any of the following combinations
   of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging
   version 2010 and Fuhrman nuclear grading.

      - pT2, G3 or G4, N0; or,

      - pT3, G any, N0; or,

      - pT4, G any, N0; or,

      - pT any, G any, N1

   - Fulfill all of the following criteria of disease-free status at baseline:

      - Had complete gross surgical resection of all RCC via radical or partial
      nephrectomy using either open or laparoscopic technique.

      - Baseline imaging of chest, abdomen and pelvis shows no metastasis or residual
      tumor lesions as confirmed centrally by an independent radiologist.

   - Received no prior adjuvant or neo-adjuvant treatment for RCC

   - Recovered from nephrectomy: any surgery related toxicities should be reduced to ≤
   grade 1 per NCI Common Terminology Criteria for Adverse Events (CTCAE) (Version 4)

   - Karnofsky performance scale (KPS) of ≥ 80

   - Adequate organ system function

Exclusion Criteria:

   - History of another malignancy. Exception: Subjects who have had another malignancy and
   have been disease-free for 5 years, or subjects with a history of completely resected
   non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible

   - Clinically significant gastrointestinal abnormalities that may increase the risk for
   gastrointestinal bleeding including, but not limited to:

      - Active peptic ulcer disease

      - Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
      gastrointestinal conditions with increased risk of perforation

      - History of abdominal fistula, gastrointestinal perforation, or intra abdominal
      abscess within 28 days prior to beginning study treatment

   - Active diarrhea of any grade

   - Clinically significant gastrointestinal abnormalities that may affect absorption of
   investigational product including, but not limited to:

      - Malabsorption syndrome

      - Major resection of the stomach or small bowel

   - History of human immunodeficiency virus (HIV) infection

   - History of active hepatitis

   - Presence of uncontrolled infection.

   - History of any one or more of the following cardiovascular conditions within the past
   6 months:

      - Cardiac angioplasty or stenting

      - Myocardial infarction

      - Unstable angina

      - Coronary artery bypass graft surgery

      - Symptomatic peripheral vascular disease

   - History of Class III or IV congestive heart failure, as defined by the New York Heart
   Association Classification of Congestive Heart Failure

   - History of cerebrovascular accident including transient ischemic attack (TIA),
   pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

   - Corrected QT interval (QTc) > 480 milliseconds (msec)

   - Poorly controlled hypertension, defined as systolic blood pressure (SBP) of ≥140 mmHg
   or diastolic blood pressure (DBP) of ≥ 90mmHg.

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
study entry. Blood pressure (BP) must be re-assessed on two occasions that are separated by
a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values
from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the
study (see Section 7.6.2 for instruction on blood pressure measurement and obtaining mean
blood pressure values).

   - Evidence of active bleeding or bleeding diathesis

   - Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
   could interfere with subject's safety, provision of informed consent, or compliance to
   study procedures

   - Unable or unwilling to discontinue use of prohibited medications for at least 14 days
   or five half-lives of a drug (whichever is longer) prior to the first dose of study
   treatment and for the duration of the study.

   - Concurrent therapy given to treat cancer including treatment with an investigational
   agent or concurrent participation in another clinical trial involving anti-cancer
   investigational drug.

   - Administration of an investigational drug within 30 days or 5 half-lives, whichever is
   longer, preceding the first dose of study treatment.

   - Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
   chemically related to pazopanib or excipients that in the opinion of the investigator
   contraindicates their participation.

   - Prior or current use of systemic anti-VEGF inhibitors, cytokines (e.g. interferon,
   interleukin 2).